Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Nasus Pharma Reports First Half 2026 Financial Results and Provides Business UpdateAppointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer
- Health GorillaHealth Gorilla Appoints Lidia Niecko-Najjum as Chief Legal Officer and Ryan Smith as Chief Technology OfficerBoth executives have worked alongside the company since last fall, shaping its technology and regulatory strategy through a period of sustained network growth. — Health Gorilla, an interoperability platform powering nationwide health data...
- MeijerMeijer Makes Immunizations More Convenient with New Scheduling Feature and Expanded Mobile Vaccine OfferingsMidwest retailer announces more options to meet customer vaccination needs heading into new school year and cold and flu season — Meijer is helping more customers take charge of their health by making recommended vaccinations easier to...
- Supra HumanSupra Human Named to Inc. 5000 for Second Consecutive Year, Ranking No. 276 NationallyOnline human performance company ranks No. 34 in Healthcare & Medical following 1,236% three-year revenue growth — Supra Human, a leading human performance and transformation company founded by former NFL athlete John Madsen and former...
- First Ascent BiomedicalFirst Ascent Biomedical Names Dr. Gilberto Lopes Chairman of Its Medical Advisory BoardUniversity of Miami medical oncology chief and Sylvester global oncology leader will guide scientific strategy, clinical evidence and the responsible advancement of Functional Precision Oncology — First Ascent Biomedical, a precision oncology...
- Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for IbezapolstatThe proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the...
- Veradigm®Veradigm to Participate in Two Upcoming Investor ConferencesCHICAGO, August 17, 2026--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management will be participating in the following investor conferences in September.
- Amirix ImagingIndependent Whitepaper Validates Amirix Imaging's LM33-T X-ray Tube for Hologic Mammography SystemsThe professional medical physicist evaluation reveals the LM33-T performs within the specification of the OEM Varex M-113T across a range of parameters (kVp accuracy, beam quality, AEC response and image quality). LOS ANGELES, Aug. 17, 2026 -- Amirix Imaging is pleased to...
- OncoC4OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous formulation designed to provide gradual systemic exposure, potentially mitigating CRS risk — ROCKVILLE, Md., Aug. 17, 2026 -- OncoC4 Inc., a...
- Sinovac Biotech Ltd.SINOVAC Reports Unaudited First Half of 2026 Financial ResultsBEIJING, August 17, 2026--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it filed its unaudited financial results for the six months ended June 30, 2026 with the U.S. Securities and Exchange Commission.
- Concentra®Concentra Strengthens Workforce Health Access in Minnesota Through AcquisitionDALLAS & MINNEAPOLIS & ST. PAUL, Minn., August 17, 2026--Concentra® (NYSE: CON), the nation's leader in occupational and workforce health services, today announced completion of its acquisition of four Minnesota Occupational Health (MOH) medical centers in the Twin Cities. The acquisition strengthens access to specialized occupational health care for Minnesota employees and connects experienced local care teams with Concentra’s national clinical and operational resources.
- Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine programEvaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma.